CONDITION

Optic glioma

An optic glioma is a tumor that grows along the nerves carrying visual information from the eyes to the brain.

WHAT IT IS
Tumor affecting the nerves between the eyes and brain

BODY SYSTEM
Nervous system and eyes

MAIN SYMPTOMS
Reduced vision, visual-field loss, eye bulging, abnormal eye movements

WHAT CAUSES IT
Usually unknown; sometimes linked to inherited NF1

HOW IT IS DIAGNOSED
MRI of optic pathways plus detailed eye testing

MAIN TREATMENT
Monitoring, chemotherapy, targeted therapy, or selected surgery

CAN IT BE CURED?
Sometimes - selected tumors can be completely removed

IS IT AN EMERGENCY?
Sometimes - sudden vision loss needs emergency assessment

LONG-TERM OUTLOOK
Many remain stable; some cause lasting vision or hormone problems

Overview

An optic glioma is a tumor that develops from supporting cells around the optic pathway. This pathway includes the optic nerves behind each eye, the point where they cross, called the optic chiasm, and the connections leading farther into the brain.

Most optic gliomas are found in children. They are usually low-grade gliomas, meaning they tend to grow more slowly than high-grade brain tumors. Many are a type called pilocytic astrocytoma. Rare optic pathway tumors in adults may behave differently, so age and the tumor's appearance matter.

An optic glioma can affect sight by pressing on or growing within the optic pathway. A tumor near the optic chiasm may also affect the nearby hypothalamus and pituitary gland, which help control growth, puberty, body temperature, sleep, and hormones.

Some tumors remain unchanged for years. Others enlarge or cause progressive loss of vision. Treatment decisions are therefore based on vision, tumor growth, symptoms, age, and location rather than the MRI result alone.

Symptoms

Changes can develop gradually and may be difficult for a young child to describe. Sometimes a problem is first noticed during an eye examination.

Possible symptoms and signs include:

A tumor involving the hypothalamus or pituitary region may contribute to unusually early puberty, changes in growth, appetite changes, or other hormone problems.

Vision loss is not always closely matched to tumor size. A tumor can look stable on MRI while vision changes, or appear larger without causing a clear decline in sight.

- Reduced or blurred vision in one or both eyes
- Loss of side vision or another part of the visual field
- Colors appearing less bright
- Eyes that do not point in the same direction
- Repetitive, uncontrolled eye movements called nystagmus
- A pale or swollen optic disc at the back of the eye
- One eye appearing to bulge forward
- Headaches, nausea, or vomiting if a larger tumor affects nearby structures

Causes and risk factors

In many people, the reason an optic glioma developed is not known. It is not caused by reading, screen use, minor eye injuries, or anything a parent did during pregnancy.

Optic gliomas are associated with neurofibromatosis type 1, usually shortened to NF1. NF1 is an inherited condition caused by a change in the NF1 gene. It can affect the skin, eyes, nerves, bones, and other parts of the body. An optic pathway glioma may be one of its complications.

Not everyone with NF1 develops an optic glioma, and many NF1-associated tumors never cause major symptoms. A child can also develop an optic glioma without having NF1.

Some low-grade gliomas contain changes affecting a cell-growth pathway called MAPK. These

changes are found in the tumor cells and may help the tumor grow. They are not necessarily inherited from a parent.

Diagnosis

Assessment usually includes a detailed eye examination and magnetic resonance imaging, or MRI. MRI uses a strong magnet and radio waves to produce images of the optic nerves, optic chiasm, and brain. Contrast material may be given into a vein to make certain areas easier to see.

Eye testing may measure:

Testing is adapted for a child's age and ability to cooperate. Repeated examinations are often more useful than a single result because they show whether vision is changing.

A biopsy removes tumor tissue for examination. It is not routinely needed when the clinical and MRI findings are typical, particularly in a child with NF1. Doctors may consider biopsy when the diagnosis is uncertain, the tumor behaves unusually, or information about tumor-cell changes could guide treatment.

Blood tests do not diagnose an optic glioma. Hormone tests may be needed if the tumor is near the hypothalamus or pituitary gland. Genetic assessment may be offered when there are signs of NF1.

- Visual sharpness in each eye
- Side vision
- Color vision
- Pupil responses and eye movements
- The appearance of the optic nerve
- The thickness of nerve fibers at the back of the eye, using optical coherence tomography

Treatment and management

Some optic gliomas do not need immediate tumor treatment. Careful monitoring may be appropriate when vision is useful and stable, symptoms are limited, and scans do not show concerning progression. Monitoring usually includes repeated eye examinations and MRI scans.

Treatment is considered when there is meaningful or repeated vision loss, troublesome tumor

growth, pressure on nearby structures, or other significant symptoms. An enlarging MRI finding alone does not always mean treatment is necessary.

Chemotherapy is commonly used for children whose low-grade optic pathway glioma needs treatment. It aims to stop or slow growth and protect remaining vision. The medicines and schedule are selected by a pediatric brain-tumor team.

Targeted medicines act on specific signals used by tumor cells. Drugs that affect the MAPK pathway may be options for certain progressive or recurrent low-grade gliomas. Whether they are suitable depends on factors such as age, previous treatment, tumor features, and local approval.

Surgery has a limited role because removing tumor from a working optic nerve or the optic chiasm can cause permanent blindness. It may be considered for a tumor confined to one optic nerve when that eye has no useful sight, especially if the eye is painful or severely pushed forward. Surgery may also be used to obtain tissue when the diagnosis is unclear.

Radiotherapy uses focused radiation to damage tumor cells. It can control some optic gliomas but may cause delayed effects involving thinking, blood vessels, hormones, growth, or second tumors. These concerns are particularly important in young children and people with NF1, so radiotherapy is generally reserved for selected situations.

Management may also include low-vision support, glasses when helpful, school accommodations, hormone care, and treatment for eye discomfort or alignment problems.

Complications

The main possible complication is permanent loss of some or all vision in the affected eye. Loss of visual field, depth perception, or color vision can occur even when central vision remains useful.

Other complications depend on the tumor's location and treatment. They can include:

Prompt recognition of a change may allow treatment to protect remaining function, but lost vision cannot always be restored.

- Eye bulging or eye-alignment problems
- Early or delayed puberty and other hormone disorders
- Problems with growth, appetite, sleep, or body temperature
- Learning or attention difficulties
- Side effects from chemotherapy, targeted treatment, surgery, or radiotherapy

Prevention

Most optic gliomas cannot be prevented. There is no known lifestyle change that prevents a sporadic tumor, and an inherited NF1 gene change cannot be prevented through diet, exercise, or screening.

For children with NF1, regular age-appropriate eye assessments can help identify vision problems early. Surveillance does not stop a tumor from forming, but it may find changes before a child can report them. Genetic counseling can explain how NF1 may be passed through a family.

Living with it and what to expect

The course differs from one person to another. Some optic gliomas remain stable without treatment, while others grow or affect vision over months or years. Tumor activity and vision can also change at different rates.

Follow-up commonly involves the same types of vision testing at each visit, together with MRI when needed. Keeping appointments is important even when vision seems unchanged. Children may not notice gradual loss in one eye because the other eye compensates.

If treatment controls the tumor, follow-up usually continues because later growth or treatment effects can occur. Hormone checks may continue when the tumor involves the pituitary or hypothalamus.

Permanent sight loss may require practical support rather than continued tumor treatment. Low-vision services can help with magnification, lighting, mobility, technology, and school or workplace adjustments. Many children continue ordinary education and activities, although some need individual learning or visual support.

Protective eyewear may be recommended for sports or activities if sight is reduced in one eye. This protects the better-seeing eye from injury; it does not alter the glioma.

When to get medical help

Seek emergency medical assessment for:

Contact the specialist team promptly for a new or gradual decline in vision, worsening side vision, new double vision, increasing eye bulging, or persistent headaches. In a child, signs may include covering one eye, bumping into objects, sitting unusually close to screens, or struggling

with previously manageable visual tasks.

Changes in growth, puberty, thirst, urination, appetite, or sleep should also be reported, particularly when the tumor is near hormone-controlling parts of the brain.

Routine follow-up is appropriate when symptoms are stable. Keep scheduled eye, imaging, cancer, and hormone appointments even if there are no obvious changes.

- Sudden, major loss of vision
- A severe or rapidly worsening headache with repeated vomiting
- New marked drowsiness, confusion, weakness, or a seizure
- Sudden eye bulging accompanied by severe pain or neurological symptoms

Common questions

Is an optic glioma cancer?

Most optic gliomas in children are low-grade tumors. They are not usually described or treated like fast-growing cancers, but they can still damage vision or nearby brain structures. Rare tumors, particularly in adults, may be more aggressive and need a different assessment.

Can an optic glioma go away on its own?

Some remain stable or become less prominent without tumor treatment. Complete disappearance is not something that can be predicted. Ongoing vision testing remains important because a stable-looking scan does not guarantee stable sight.

Will an optic glioma cause blindness?

Not always. Some people keep useful vision for many years, while others lose vision in one or both eyes. The risk is influenced by the tumor's location, its behavior, the person's age, and how vision responds to treatment.

Does every optic glioma need treatment?

No. Monitoring can be appropriate when vision and other symptoms are stable. Treatment is more likely when repeated testing shows meaningful vision loss, the tumor is causing other health problems, or its growth threatens important structures.

Can surgery restore vision?

Surgery usually cannot restore vision already lost from damage to the optic pathway. Because operating on the optic nerve or chiasm can remove remaining sight, surgery is reserved for particular circumstances rather than used routinely.

Does having an optic glioma mean I have NF1?

No. Optic gliomas can occur without NF1. However, an assessment for NF1 may be appropriate when there are other features, such as café-au-lait skin patches, freckling in unusual areas, certain eye findings, nerve tumors, or a family history.

Sources

- National Cancer Institute. Childhood Astrocytomas and Other Gliomas Treatment (PDQ®)-Health Professional Version
- National Cancer Institute. Neurofibromatosis Type 1 and Cancer
- Friedman JM. Neurofibromatosis 1 . GeneReviews®, University of Washington, Seattle
- de Blank PMK, Fisher MJ, Liu GT, and colleagues. "Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update-Surveillance, Treatment Indications, and Biomarkers of Vision." Journal of Neuro-Ophthalmology . 2017;37(Supplement 1):S23-S32
- Carton C, Evans DG, Blanco I, and colleagues. "ERN GENTURIS Tumour Surveillance Guidelines for Individuals with Neurofibromatosis Type 1." eClinicalMedicine . 2023;56:101818
- World Health Organization Classification of Tumours Editorial Board. Central Nervous System Tumours . WHO Classification of Tumours, 5th edition. International Agency for Research on Cancer; 2021